Catalyst down but not out on second trial failure of cocaine addiction drug

Catalyst Pharmaceutical Partners lost 65.5% of its market value on 8 November based on the not particularly surprising news that CPP-109 (vigabatrin), its drug therapy for cocaine addiction, did not meet primary or secondary endpoints in a Phase IIb clinical trial.

The Coral Gables, Florida-based company's stock sank from $1.45 to $0.50 per share - the lowest price reached this year - bringing its market cap to $15.4 million.